Cinacalcet HCl, an Oral Calcimimetic Agent for the Treatment of Secondary Hyperparathyroidism in Hemodialysis and Peritoneal Dialysis
Authors:
- Jill S. LindbergJLJill S. Lindberg
- Bruce CulletonBCBruce Culleton
- Gordon WongGWGordon Wong
- Michael F. BorahMBMichael F. Borah
- Roderick V. ClarkRCRoderick V. Clark
- Warren B. ShapiroWSWarren B. Shapiro
- Simon D. RogerSRSimon D. Roger
- Fred E. HusserlFHFred E. Husserl
- Preston S. KlassenPKPreston S. Klassen
- Matthew D. GuoMGMatthew D. Guo
- Moetaz B. AlbizemMAMoetaz B. Albizem
- Jack W. CoburnJCJack W. Coburn
- 1 March 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 16 (3) , 800-807
Abstract
Management of secondary hyperparathyroidism is challenging with traditional therapy. The calcimimetic cinacalcet HCl acts on the calcium-sensing receptor to increase its sensitivity to calcium, thereby reducing parathyroid hormone (PTH) secretion. This phase 3, multicenter, randomized, placebo-controlled, double-blind study evaluated the efficacy and safety of cinacalcet in hemodialysis (HD) and peritoneal dialysis (PD) patients with PTH ≥300 pg/ml despite traditional therapy. A total of 395 patients received once-daily oral cinacalcet (260 HD, 34 PD) or placebo (89 HD, 12 PD) titrated from 30 to 180 mg to achieve a target intact PTH (iPTH) level of ≤250 pg/ml. During a 10-wk efficacy assessment phase, cinacalcet was more effective than control for PTH reduction outcomes, including proportion of patients with mean iPTH levels ≤300 pg/ml (46 versus 9%), proportion of patients with ≥30% reduction in iPTH from baseline (65 versus 13%), and proportion of patients with ≥20, ≥40, or ≥50% reduction from baseline. Cinacalcet had comparable efficacy in HD and PD patients; 50% of PD patients achieved a mean iPTH ≤300 pg/ml. Cinacalcet also significantly reduced serum calcium, phosphorus, and Ca × P levels compared with control treatment. The most common side effects, nausea and vomiting, were usually mild to moderate in severity and transient. Once-daily oral cinacalcet was effective in rapidly and safely reducing PTH, Ca × P, calcium, and phosphorus levels in patients who received HD or PD. Cinacalcet offers a new therapeutic option for controlling secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.Keywords
This publication has 2 references indexed in Scilit:
- High Prevalence of Hyperparathyroidism among Peritoneal Dialysis Patients: A Review of 176 PatientsPeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2000
- Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia.Clinical Chemistry, 1987